the influence of the dosing regimen on the occurrence of oropharyngeal complications during a trial of the anti-asthmatic aerosol steroid budesonide was assessed by systematically varying the daily dose ( 400 , 800 , 1,600 micrograms ) , dose frequency ( b.i.d . vs . q.i.d . ) , and dosing schedule ( am vs. am/pm ) .
C0004096
asthmatic
C0054201
budesonide